|Table of Contents|

Clinical analysis of 134 cases of neuroblastoma in children

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4356-4361
Research Field:
Publishing date:

Info

Title:
Clinical analysis of 134 cases of neuroblastoma in children
Author(s):
HE Jing; LI Jiazhuo; TIAN Xin; CHEN Keke; ZOU Runying; ZHU Chengguang; HE Xiangling
Department of Pediatric Hematology Oncology,Hunan Provincial People's Hospital,the First Affiliated Hospital of Hunan Normal University,Hunan Changsha 410005,China.
Keywords:
neuroblastoma; children; clinical analysis
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2023.23.011
Abstract:
Objective:To analyze the general information,clinical data,treatment status,and prognosis of children with neuroblastoma(NB),in order to provide reference for the clinical diagnosis and treatment of NB.Methods:A retrospective analysis was conducted on 134 pediatric patients with NB who were treated and followed up in our hospital from January 2016 to December 2022.General and clinical data of the patients were collected,and event free survival(EFS) and overall survival(OS) were statistically analyzed.Results:134 subjects were included in the study,with a male and female ratio of 1.6∶1,and a median onset age of 3.0 years old.82.6% of the patients had onset age≤5 years old.The majority of tumors originated from the abdomen in 109 cases(81.3%).The first symptom was mostly fever in 36 cases(26.9%),followed by 31 cases(23.1%) of mediastinal masses or abdominal masses found during physical examination.65.5% of high-risk NB patients had lymph node metastasis.93.2% of the children had elevated LDH values,with the highest LDH value in the high-risk group.There was a statistically significant difference in LDH values between different risk groups(P＜0.05).86.5% of the children had an increase in NSE value,while 42.1%(48 cases) had an increase in urinary VMA value.There was no statistically significant difference in NSE and VMA values among different risk groups(P＞0.05).The overall 5-year EFS of 125 children who completed complete treatment was 46.5%,and OS was 72.0%.High-risk children had a 5-year EFS of 25.1% and OS of 63.6%.Conclusion:The primary site of tumors mostly comes from the abdomen,and fever is often the first symptom.After multidisciplinary comprehensive diagnosis and treatment,the 5-year EFS was 46.5% and 5-year OS was 72.0% in 125 NB children who completed complete treatment.And among these high-risk children,the 5-year EFS is 25.1% and 5-year OS is 63.6%.

References:

［1］QIU B,MATTHAY KK.Advancing therapy for neuroblastoma［J］.Nat Rev Clin Oncol,2022,19(8):515-533.
［2］JORG OTTE，CECILIA DYBERG，ADENA PEPICH,et al.MYCN function in neuroblastoma development［J］.Frontiers in Oncology,2020,10:624079.
［3］VAN HJ,KRUGER M.Management of neuroblastoma in limited-resource settings［J］.World J Clin Oncol,2020,11(8):629-643.
［4］PUDELA C,BALYASNY S,APPLEBAUM MA.Nervous system:Embryonal tumors:Neuroblastoma［J］.Atlas Genet Cytogenet Oncol Haematol,2020,24(7):284-290.
［5］JORG OTTE,CECILIA DYBERG.MYCN function in neuroblastoma development［J］.Frontiers in Oncology,2020,10:624079.
［6］中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤外科学组.儿童神经母细胞瘤诊疗专家共识［J］.中华小儿外科杂志,2015,36(1):3-7. Chinese Children Cancer Group,Oncology Branch of Pediatric Surgery Society of Chinese Medical Association.Expert consensus on diagnosis and treatment of neuroblastoma in children(2015)［J］.Chin J Pediatr Surg,2015,36(1):3-7.
［7］中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤学组.儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案［J］.中华小儿外科杂志,2022,43(7):588-598. Chinese Children Cancer Group,Oncology Branch of Pediatric Surgery Society of Chinese Medical Association.Expert consensus on diagnosis and treatment of neuroblastoma in children(2021)［J］.Chin J Pediatr Surg,2022,43(7):588-598.
［8］STELIAROVA-FOUCHER E,COLOMBET M,RIES LAG,et al.International incidence of childhood cancer,2001-10:A population-based registry study［J］.Lancet Oncol,2017,18(6):719-731.
［9］刘颖，孙艳丽，程士凯，等.小儿神经母细胞瘤肺转移临床特征分析［J］.现代肿瘤医学，2013,21（3）：604-607. LIU Y,SUN YL,CHENG SK,et al.Clinical analysis of pulmonary metastases at diagnosis of neuroblastoma in pediatric patients［J］.Modern Oncology，2013,21（3）：604-607.
［10］WHITTLE SB,SMITH V,DOHERTY E,et al.Overview and recent advances in the treatment of neuroblastoma［J］.Expert Rev Anticancer Ther,2017,17(4):369-386.
［11］QI Y,ZHAN J.Roles of surgery in the treatment of patients with highrisk neuroblastoma in the children oncology group study:A systematic review and Meta-analysis［J］.Front Pediatr,2021,9:706800.
［12］SUN X,ZHEN Z,GUO Y,et al.Oral metronomic maintenance therapy can improve survival in highrisk neuroblastoma patients not treated with ASCT or anti-GD2 antibodies［J］.Cancers,2021,13(14):3494.
［13］GIULIANI S.Novel treatments and technologies applied to the cure of neuroblastoma［J］.Children(Basel,Switzerland),2021,8(6):482.
［14］马晓莉，彭晓霞，段超，等.疑似儿童神经母细胞瘤识别及转诊指南［J］.中国循证医学杂志,2022,22(11):1241-1248. MA XL,PENG XX,DUAN C,et al.Guidelines of identification and referral of suspected neuroblastoma in children［J］.Chin J Evid-based Med,2022,22(11):1241-1248.
［15］SUN Q,CHEN Y,JIN Q,et al.A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma［J］.Eur J Pediatr,2022,181(12):4135-4147.
［16］SIMON T,HERO B,HUNNEMAN DH,et al.Tumour markers are poor predictors for relapse or progression in neuroblastoma［J］.Eur J Cancer,2003,39(13):1899-1903.
［17］MOROZ V,MACHIN D,HERO B,et al.The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma:A report from the International Neuroblastoma Risk Group(INRG) project［J］.Pediatr Blood Cancer,2020,67(8):e28359.
［18］IRWIN MS,NARANJO A,ZHANG FF,et al.Revised neuroblastoma risk classification system:A report from the Children's Oncology Group［J］.J Clin Oncol,2021,39(29):3229-3241.
［19］MONCLAIR T,MOSSERI V,CECCHETTO G,et al.Influence of image-defined risk factors on the outcome of patients with localised neuroblastoma.A report from the LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group［J］.Pediatr Blood Cancer,2015,62(9):1536.
［20］NEWMAN EA,ABDESSALAM S,ALDRINK JH,et al.Update on neuroblastoma［J］.J Pediatr Surg,2019,54(3):383.
［21］HOLMES K,POTSCHGER U,PEARSON ADJ,et al.Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma:A report from the HR-NBL1/SIOPEN study［J］.J Clin Oncol,2020,38(25):2902-2915.
［22］PAI PANANDIKER AS,BELTRAN C,BILLUPS CA,et al.Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma［J］.Pediatr Blood Cancer,2013,60(5):761-765.
［23］袁晓军.GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识(2021年版)［J］.临床儿科杂志,2022,40(1):14-20. YUAN XJ.Expert consensus on GD2 antibody datuximab β clinical application of treatment for neuroblastoma(2021)［J］.J Chin Pediatr,2022,40(1):14-20.
［24］LADENSTEIN R,POTSCHGER U,VALTEAU-COUANET D,et al.Investigation of the role of dinutuximab Beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial(HR-NBL1)［J］.Cancers(Basel),2020,12(2):309.

Memo

Memo:
-
Last Update: 2023-10-31